drugset / Trial / NCT01263782
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
Phase 2
Completed
64 enrolled
M.D. Anderson Cancer Center
Eli Lilly and Company · collabGenentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if knowing biomarker status can help researchers find better treatment combinations for patients with advanced NSCLC. Researchers want to use biomarker status to decide what drug (bevacizumab, or cixutumumab) to give in combination with carboplatin and pemetrexed. The safety of these drug combinations will also be studied.
Timeline
- Start
- 2011-05-17
- Primary completion
- 2017-08-15
- Completion
- 2017-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Cixutumumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |